Clinical trials: Fatigue in Multiple Sclerosis
Multiple Sclerosis
Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon
The study aims to investigate the relationship between sleep quality, quality of life,other disorders and therapies in Multiple Sclerosis (MS) patients treated with Betaferon.
- Trial name
- BetaSleep (NCT01766063)
- Testing
- Interferon beta-1b (Betaferon, BAY 86-5046)
- Where
- Germany
- Volunteers
- 138 people
- Sponsor
- Bayer
Multiple Sclerosis, Relapsing-Remitting
Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®
The study is planned to evaluate the cognitive functions in subjects with RRMS treated with interferon beta-1a, and its relationship to the fatigue and neurological dysfunction status.
- Trial name
- SKORE (NCT01075880)
- Testing
- Rebif (Interferon beta-1a)
- Where
- 13 sites in Czechia
- Volunteers
- 300 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Relapsing-remitting
A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina
This is an observational, non-controlled, multicentric, prospective study planned to be conducted in 66 subjects diagnosed with multiple sclerosis (MS) in 20 centres of Argentina.
- Trial name
- NCT01080001
- Where
- Argentina
- Volunteers
- 71 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Physical Activity and Fatigue in Early Multiple Sclerosis (MS)
The purpose of this observational study is to obtain a survey on physical activity in patients who for the first time have experienced symptoms which indicate a high risk for developing multiple sclerosis (MS) and in patients…
- Trial name
- BEGIN (NCT00882453)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 33 sites in Australia, Austria and 31 more
- Volunteers
- 1,739 people
- Sponsor
- Bayer
Multiple Sclerosis
Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)
The purpose of the study was the evaluation of the effect of a treatment for highly-active relapsing multiple sclerosis (RMS). This was the extension study to CLARIFY MS (NCT03369665), to assess cognitive impairment and health…
- Trial name
- NCT04776213
- Testing
- Mavenclad®
- Where
- 60 sites in Austria, Czechia and 8 more
- Volunteers
- 280 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate
The primary objective of this study is to determine whether dimethyl fumarate (DMF) taken over 12 months is effective in reducing Multiple Sclerosis (MS)-related fatigue, as measured by mean changes in the Fatigue Scale for Motor…
- Trial name
- TECNERGY (NCT02090348)
- Testing
- dimethyl fumarate
- Sponsor
- Biogen
Multiple Sclerosis
Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis
Fampyra, a voltage-dependent potassium channel blocker, is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7).
- Trial name
- FAMILY (NCT03164018)
- Testing
- Fampridine
- Where
- Greece
- Volunteers
- 111 people
- Sponsor
- Genesis Pharma CNS & Specialty
Relapsing-Remitting Multiple Sclerosis, Fatigue
Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS
The primary objective of this trial is to observe the Multiple Sclerosis (MS) related fatigue during treatment with Tysabri as measured by changes in the fatigue scale for motor and cognitive functions (FMSC) over the course of…
- Trial name
- TYNERGY (NCT00884481)
- Testing
- Natalizumab
- Where
- 27 sites in Austria, Denmark and 2 more
- Volunteers
- 195 people
- Sponsor
- Biogen
Spasticity, Multiple Sclerosis
One Year Extension Study To Protocol C2/5/TZ:MS-05
Open label, one year extension study to evaluate the clinical efficacy and safety of 12 mg sublingual tizanidine administered once nightly in MS patients who successfully completed Phase I/II protocol C2/5/TZ:MS-05 at the Tel…
- Trial name
- NCT00464958
- Testing
- sublingual tizanidine 12 mg
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Teva GTC
Fatigue in Multiple Sclerosis
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
This study evaluated the effect of an individualized web-based physical training in fingolimod -treated patients.
- Trial name
- PACE (NCT01490840)
- Testing
- Physical exercise
- Where
- 32 sites in Germany
- Volunteers
- 178 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Virtual Reality - Gamma Sensory Stimulation for Improving Fatigue in People With Multiple Sclerosis
This is a double-blind, parallel, randomized, sham-controlled pilot study evaluating the safety, feasibility, and efficacy of Gamma Sensory Stimulation (GSS) delivered via a Virtual Reality (VR) headset in individuals with…
- Trial name
- VR-GSS (NCT07310862)
- Testing
- Virtual Reality Gamma Sensory Stimulation
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Clarity Health Technologies, Inc
Multiple Sclerosis
FOCUS Fatigue Outcome in Copaxone USers
The study primarily investigates the effect of copaxone on fatigue during treatment, compared to baseline in patients with relapsing-remitting multiple sclerosis.
- Trial name
- NCT00267319
- Testing
- Glatiramer acetate
- Where
- Czechia
- Volunteers
- 111 people
- Sponsor
- Sanofi
Multiple Sclerosis
Depression and Fatigue in MS Patients Treated With Betaferon.
This study aims to evaluate the occurence and severity of fatigue and depression in multiple sclerosis patients and the impact of Betaferon treatment on symptoms alterations.
- Trial name
- FADO (NCT01354665)
- Testing
- Interferon beta-1b (Betaferon, BAY86-5046)
- Where
- Poland
- Volunteers
- 567 people
- Sponsor
- Bayer
Multiple Sclerosis
Evaluation of Natalizumab for thE Relief of MS Associated FatiGue
This study aims to study the effects of TYSABRI® treatment on fatigue and cognition in patients with relapsing forms of MS.
- Trial name
- ENER-G (NCT00464074)
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 89 people
- Sponsor
- Biogen
Exercise
A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multiple Sclerosis
The primary objective of the investigation is to determine whether the addition of exercise (resistance training or modified physiotherapy) improves functional capacity in Multiple Sclerosis (MS) participants undergoing Disease…
- Trial name
- ACTIMS (NCT01065090)
- Where
- 14 sites in Australia, Denmark and 4 more
- Volunteers
- 38 people
- Sponsor
- Biogen